ClinicalTrials.gg
CompletedNCT01336777Updated Dec 4, 2024

Regional Fat Depots and Insulin Resistance

An observational study in Obesity, Insulin Resistance and Diabetes Mellitus Type 2, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 39 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Stanford University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
166
Ages
39 Years to 65 Years
Sex
All
01

Study summary

The biological basis for insulin resistance associated with obesity is unknown. By studying equally-overweight/obese individuals who are either insulin resistant or insulin sensitive, the investigators will compare characteristics of fat tissue to test several hypotheses: 1) impaired differentiation and fat storage in the subcutaneous fat depot characterize insulin resistant individuals, who have, as a result, fat in other tissues like liver and muscle, as well as more fat circulating in the blood; 2) inflammation is greater in visceral and/or subcutaneous adipose tissue depots in insulin resistant individuals as compared with insulin sensitive individuals.

Read the detailed description

Insulin resistance (IR) is a major contributor to obesity-related morbidities such as diabetes and cardiovascular disease. While obesity is associated with IR, the biological basis for this association is unclear, and not all obese individuals are IR. The once-popular portal hypothesis, which states that lipolysis from VAT in particular accounts for IR, has been questioned because VAT contributes only 15% of the total systemic free fatty acid (FFA) flux. Other proposed mechanisms linking obesity to IR include inflammation, adiponectin, and ectopic fat. It is unclear whether VAT mass is more closely linked to IR than is subcutaneous adipose tissue (SAT) mass. Furthermore, evidence linking differential biological activity to IR in VAT or SAT is indirect, largely derived from studies comparing lean to obese or VAT to SAT without evaluation of IR. Thus, the purpose of this study is to investigate the biological mechanisms by which SAT and/or VAT contribute to IR. Specifically, the investigators will explore two related hypotheses- that impaired adipocyte differentiation in SAT is related to IR, ectopic fat deposition and expansion of VAT depot, and that inflammation in VAT is associated with IR. Utilizing adipose cell size/distribution obtained by Beckman Coulter Multisizer, gene expression via quantitative PCR, in-vivo quantification of IR via a modified insulin suppression test, and CT scans of abdomen/thigh, our specific aims are to:

  1. Confirm that impairment of adipocyte differentiation in SAT is associated with IR by comparing cell size characteristics and differentiation markers in IR and IS subjects undergoing elective surgery;
  2. Test the hypothesis that the same relationship will not be seen in VAT;
  3. Demonstrate that VAT mass is expanded in the presence of impaired differentiation of adipocytes in SAT;
  4. Demonstrate that intramuscular fat is related to both IR and impaired differentiation of adipocytes in SAT using cell size characteristics and differentiation markers;
  5. Demonstrate that increased inflammation in omental fat is associated with IR independent of obesity using inflammation markers (gene and protein).
02

Conditions studied

  • Obesity
  • Insulin Resistance
  • Diabetes Mellitus Type 2

Keywords

  • obesity
  • adipocyte differentiation
  • inflammation
  • insulin resistance
  • visceral fat
  • regional fat depots
03

In context

Obesity

6,570 studies on the registry are indexed under Obesity; 1,718 are open to participants now.

This study's enrollment of 166 is above the median of 132 across 1,338 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Stanford University is the lead sponsor of 2,161 studies on the registry; 428 are open to participants now.

Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
39 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy, nondiabetic volunteers will be recruited from Stanford's General Surgery Preoperative Clinic, Stanford's Bariatric Surgery Clinic, and nonsurgical volunteers who respond to local newspaper advertisements.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No major organ disease
  • Fasting blood glucose \< 126 mg/dL
  • BMI 25-35 kg/m2
  • Nonpregnant/nonlactating

Exclusion criteria

Exclusion Criteria:

  • pregnancy/lactation
  • major organ disease
  • drugs that influence insulin resistance
  • unstable body weight or active weight loss program
  • outside BMI range or age range
  • diabetic by fasting glucose criteria 126 mg/dL or higher
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
166 participants (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Insulin resistant group

    there is no intervention

  • Insulin sensitive group

    There is no intervention

06

What researchers measure

Primary outcomes

  1. Adipose Cell Size

    Harvest adipose tissue from human biopsy. Prepare for cell size analysis using Beckman Multisizer Coulter Counter

    Time frame: 3 years

Secondary outcomes

  1. Macrophage density

    Human adipose tissue will be formalin-fixed and paraffin-blocked for immunohistochemical analysis to identify macrophage number and pattern

    Time frame: 3 years

  2. Gene Expression

    Adipose tissue from humans will be frozen and RNA prepared for measurement of relative expression of genes related to adipose cell differentiation, fat storage, and inflammation

    Time frame: 3 years

07

Study locations

1 site
  • Stanford University
    Stanford, California 94305, United States
08

References and documents

Publications

  • McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab. 2011 Nov;96(11):E1756-60. doi: 10.1210/jc.2011-0615. Epub 2011 Aug 24. PubMed 21865361 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2009 to primary completion in May 2013, 45 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2011
First posted
Apr 18, 2011
StartActual
Aug 2009
Primary completionActual
May 2013
CompletionActual
May 2013
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01336777
Collaborators
University of California, National Institutes of Health (NIH)
Responsible party
Tracey McLaughlin (Associate Professor, Stanford University) — Principal investigator
First posted
Apr 18, 2011
Start date
Aug 2009
Primary completion
May 2013
Completion
May 2013
Last update
Dec 4, 2024

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion